A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death

Jonathan Mannion(Institute of Cancer Research), Pascal Meier(Breast Cancer Now)
Immunity
May 23, 2024
Cited by 80


Related Papers